INDIAGLYCO NSE filing

India Glycols Ltd Presents Q2 & H1 FY27 Investor Presentation

The RealCase readHigh impact Positive

India Glycols Ltd reported strong Q2 FY27 results with revenue up 30% YoY to ₹358 Cr and EBITDA up 26% YoY to ₹52 Cr. H1 FY27 revenue grew 26% to ₹713 Cr, and EBITDA rose 25% to ₹113 Cr. Bio-based specialty materials revenue surged 43% in H1. The company is focused on a specialty-led portfolio and projects significant long-term growth.

Why it matters

The announcement provides a comprehensive update on the company's financial performance, strategic direction, and future outlook, including detailed segment performance and financial highlights. This level of detail is crucial for investors and stakeholders.

The market read

The company reported significant year-on-year growth in revenue and EBITDA for both Q2 and H1 FY27, driven by strong performance in its key business segments. The strategic focus on specialty materials and a positive outlook contribute to a positive sentiment.

India Glycols Limited (IGL) has released its investor presentation for the second quarter (Q2) and first half (H1) of the fiscal year 2027. The presentation highlights strong growth momentum, with Q2 FY27 revenue increasing by 30% year-on-year (YoY) to ₹358 Crore, and H1 revenue growing by 26% YoY to ₹713 Crore.

EBITDA also saw healthy growth, with a 26% YoY increase in Q2 to ₹52 Crore and a 25% YoY increase in H1 to ₹113 Crore. The company's Bio-based Specialty Materials segment led the growth, with H1 revenue up 43% YoY to ₹382 Crore. The Sustainable & Performance Chemicals segment demonstrated operating leverage, with Q2 revenue growing 36% to ₹167 Crore and H1 revenue growing 29% to ₹313 Crore. EBITDA for this segment increased by 49% in Q2 and 40% in H1.

The presentation also details the company's strategic shift towards a more specialty-led portfolio, with Bio-Based Specialty Materials increasing their share of H1 revenue to 55%. The outlook suggests steady growth for specialty materials and performance chemicals, driven by new product introductions and technological advancements.

IGL emphasizes its position as a pure-play chemicals company following the demerger of its spirits and biopharma businesses. The company highlights its integrated value chain, from renewable ethanol to derivatives, and its strong market position in bio-based chemicals. The presentation also touches upon the operating environment, including the impact of global events and currency fluctuations on its business segments. Key financial highlights for Q2 and H1 FY27 are provided, alongside a look at the balance sheet and cash flow statements. The company outlines a three-horizon roadmap, aiming for significant sales and profit growth over the next decade, driven by its focus on sustainable specialty materials, performance chemicals, and novel carbon technologies. The presentation concludes by underscoring six drivers for its growth vision, including its leadership in bio-based specialty chemicals, a structural shift towards a specialty-led portfolio, and favorable industry dynamics.

Filing to action

What to do with a filing like this

India Glycols Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by India Glycols Limited. Read the original for the full detail.

View original filing